It has demonstrated potent anti-tumor activity in MTAP-null cancer cell lines and tumor xenograft models and will be further studied in a first-in-human phase I/II trial in patients with advanced solid tumors with confirmed MTAP deletion (NCT05094336) [167]. Here, MTAP is linked to cancer.